Analyst: Novo’s product is superior, but…
![Foto: Jens Lindhe](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article6943017.ece/ALTERNATES/schema-16_9/Novo%2520Nordisk%2520hovedkvarter.jpg)
Late last month, the French-based drug group Sanofi reported positive phase III data for its combination product LixiLan, marking another chapter in the group's ongoing battle for control of the all important US diabetes market with Danish-based rival Novo Nordisk.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Zealand CEO: A news-heavy year
For abonnenter
Novo’s handpicked dozen to decide Tresiba’s fate
For abonnenter
Here are the most important results from ADA
For abonnenter